Xuan Gu Bao·2025-09-01 08:49Market Overview - The Shanghai Composite Index experienced a sideways movement throughout the day, while the ChiNext Index rose over 2% in the afternoon. Gold stocks surged collectively, with companies like Western Gold and Hunan Gold hitting the daily limit. Chip stocks continued their strong performance, with companies such as Zhaoyi Innovation and Wanrun Technology also reaching the limit. The innovative drug concept was actively traded, with Ji Min Health and Kangchen Pharmaceutical hitting the limit. The CPO and other computing hardware stocks saw significant gains, with Guangku Technology and Zhongji Xuchuang rising over 10% to reach new highs. Overall, approximately 3,100 stocks in the Shanghai and Shenzhen markets rose, with a total transaction volume of 2.77 trillion yuan [1]. Hot Topics Gold - The gold sector saw a significant increase, with multiple stocks such as Western Gold, Silver Nonferrous, and Hunan Silver hitting the daily limit. This surge was catalyzed by international gold prices reaching a historical high, with silver breaking the $40 mark for the first time since 2011, and futures rising over 4% [4]. - The latest price for Western Gold was 21.91 yuan, up 9.99%, with a market cap of 14.99 billion yuan. Hunan Gold reached 22.74 yuan, up 10.01%, with a market cap of 35.53 billion yuan. Other notable performers included Silver Nonferrous and Hunan Silver, both hitting the daily limit [5]. Domestic Chips - The domestic chip sector experienced another significant rise, with Tianpu Co. achieving seven consecutive limits and Jianye Co. four consecutive limits. Companies like Xuanji Information and Liyang Chip also hit the limit. Reports indicated that TSMC notified clients of a 5-10% increase in foundry prices for 2026 [7]. - Alibaba has developed a new AI chip to fill the gap left by Nvidia in the Chinese market. Additionally, Huahong announced plans to acquire a 97.5% stake in Huali Micro and raise supporting funds [7][10]. Pharmaceuticals - The pharmaceutical sector saw a notable increase, with Ji Min Health hitting the limit and companies like Kangchen Pharmaceutical and Huahai Pharmaceutical achieving consecutive limits. The National Medical Products Administration reported that China's biopharmaceutical market has become the second largest globally, with innovative drugs accounting for about 30% of global research [11]. - The total amount of foreign authorization for innovative drugs reached nearly $66 billion in the first half of 2025, indicating a growing recognition of Chinese innovative drugs in the global market [11]. Additional Insights - Analysts predict that the domestic innovative drug industry will reach a turning point in 2025, shifting from capital-driven to profit-driven growth, supported by ongoing fundamentals and policies [14]. - The gold and silver markets are expected to benefit from anticipated interest rate cuts by the Federal Reserve, which could support commodity prices overall [6].